Physician profile
Warit Jithpratuck
NPI 1942462924
$23,963.61
in general payments reported to CMS, 2019-2025
44 companies · $8,765 in 2025
The $8,765 reported for 2025 was more than what 87% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,760 · 2020: $476 · 2021: $767 · 2022: $3,005 · 2023: $3,731 · 2024: $4,459 · 2025: $8,765.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Consulting Fee: $5,354 · Education: $256 · Travel and Lodging: $66.28.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,279.82 |
| Consulting Fee | $5,353.50 |
| Education | $255.63 |
| Travel and Lodging | $66.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $5,969.95 | 2019-2025 | Hizentra, Andembry, Haegarda |
| Glaxosmithkline, LLC. | $2,420.96 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals LP | $2,079.62 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Takeda Pharmaceuticals U.S.A., INC. | $1,582.09 | 2021-2025 | Takhzyro, Cuvitru, Eohilia |
| Regeneron Healthcare Solutions, INC. | $1,276.11 | 2019-2025 | Dupixent |
| Genzyme Corporation | $1,229.65 | 2019-2025 | |
| Biocryst US Sales Co., LLC | $1,212.47 | 2022-2025 | Orladeyo |
| Allerderm Laboratories | $1,000.00 | 2019 | |
| Optinose US, INC. | $734.85 | 2020-2025 | |
| Novartis Pharmaceuticals Corporation | $521.51 | 2020-2025 | |
| Genentech USA, INC. | $518.36 | 2019-2024 | Xolair |
| Pfizer INC. | $517.64 | 2020-2025 | |
| Beigene USA, INC. | $460.00 | 2024 | |
| Becton, Dickinson and Company | $400.00 | 2024 | |
| Pharming Healthcare, INC. | $364.27 | 2019-2025 | Ruconest |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Octapharma USA, INC. | $363.92 | 2020-2024 | Cutaquig |
| Amgen INC. | $317.63 | 2022-2025 | Tezspire, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $310.98 | 2020-2023 | Spiriva Respimat, Spiriva |
| Abbvie INC. | $294.84 | 2022-2023 | |
| Grifols USA, LLC | $293.59 | 2022-2025 | Xembify, Prolastin-C Liquid |
| Aimmune Therapeutics, INC. | $266.87 | 2020-2022 | |
| Kaleo, INC. | $234.93 | 2019-2024 | Auvi-Q |
| Blueprint Medicines Corporation | $213.00 | 2023-2025 | Ayvakit |
| Covis Pharma Gmbh | $158.30 | 2021-2022 | |
| Adma Biomanufacturing LLC | $150.00 | 2024 | |
| Ars Pharmaceuticals Operations, INC. | $136.47 | 2025 | Neffy |
| Lilly USA, LLC | $124.09 | 2025 | Ebglyss |
| Leo Pharma INC. | $108.90 | 2022-2025 | Adbry |
| Phadia US INC. | $101.30 | 2019-2024 | Immunocap |
| Greer Laboratories, INC. | $93.82 | 2024-2025 | Oralair |
| Alk-Abello, INC | $89.40 | 2019-2022 | |
| Galderma Laboratories, L.P. | $69.43 | 2025 | Nemluvio |
| Cycle Pharmaceuticals INC | $58.61 | 2024-2025 | Sajazir |
| Incyte Corporation | $40.31 | 2022-2024 | Opzelura |
| Shire North American Group INC | $35.44 | 2019 | |
| Bio Products Laboratory USA, INC. | $34.03 | 2021-2022 | |
| Ionis Pharmaceuticals, INC. | $29.15 | 2025 | Dawnzera |
| Azurity Pharmaceuticals, INC. | $27.45 | 2025 | Alvesco |
| Organon LLC | $26.06 | 2025 | |
| Gc Biopharma USA, INC. | $22.54 | 2025 | Alyglo |
| Hikma Pharmaceuticals USA | $21.25 | 2023 | Ryaltris |
| Arcutis Biotherapeutics, INC. | $18.45 | 2024 | Zoryve |
| Teva Pharmaceuticals USA, INC. | $17.88 | 2020 | |
| Merck Sharp & Dohme LLC | $17.49 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Warit Jithpratuck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.